{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:47:00Z","timestamp":1785466020993,"version":"3.56.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T00:00:00Z","timestamp":1593388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T00:00:00Z","timestamp":1593388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","award":["3M180506"],"award-info":[{"award-number":["3M180506"]}],"id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Childs Nerv Syst"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s00381-020-04771-8","type":"journal-article","created":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T22:02:40Z","timestamp":1593468160000},"page":"2285-2295","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Genetic basis of neurofibromatosis type 1 and related conditions, including mosaicism"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2410-6996","authenticated-orcid":false,"given":"Eric","family":"Legius","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0325-4060","authenticated-orcid":false,"given":"Hilde","family":"Brems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,29]]},"reference":[{"key":"4771_CR1","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/jid.2014.465","volume":"135","author":"E Uusitalo","year":"2015","unstructured":"Uusitalo E, Lepp\u00e4virta J, Koffert A, Suominen S, Vahtera J, Vahlberg T, P\u00f6yh\u00f6nen M, Peltonen J, Peltonen S (2015) Incidence and mortality of neurofibromatosis: a total population study in Finland. J Invest Dermatol 135:904\u2013906","journal-title":"J Invest Dermatol"},{"key":"4771_CR2","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/ajmg.a.33139","volume":"152A","author":"DG Evans","year":"2010","unstructured":"Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, Lalloo F (2010) Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A 152A:327\u2013332","journal-title":"Am J Med Genet A"},{"key":"4771_CR3","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1038\/gim.2017.215","volume":"20","author":"RA Kallionp\u00e4\u00e4","year":"2018","unstructured":"Kallionp\u00e4\u00e4 RA, Uusitalo E, Lepp\u00e4virta J, P\u00f6yh\u00f6nen M, Peltonen S, Peltonen J (2018) Prevalence of neurofibromatosis type 1 in the Finnish population. Genet Med 20:1082\u20131086","journal-title":"Genet Med"},{"key":"4771_CR4","doi-asserted-by":"publisher","first-page":"17004","DOI":"10.1038\/nrdp.2017.4","volume":"3","author":"DH Gutmann","year":"2017","unstructured":"Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ (2017) Neurofibromatosis type 1. Nat Rev Dis Primers 3:17004","journal-title":"Nat Rev Dis Primers"},{"key":"4771_CR5","unstructured":"(1988) National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, Md., USA, July 13\u201315, 1987. Neurofibromatosis 1: 172\u2013178"},{"key":"4771_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1126\/science.2134734","volume":"249","author":"MR Wallace","year":"1990","unstructured":"Wallace MR, Marchuk DA, Andersen LB, Letcher R, Odeh HM, Saulino AM, Fountain JW, Brereton A, Nicholson J, Mitchell AL (1990) Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 249:181\u2013186","journal-title":"Science"},{"key":"4771_CR7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/0092-8674(90)90252-A","volume":"62","author":"D Viskochil","year":"1990","unstructured":"Viskochil D, Buchberg AM, Xu G, Cawthon RM, Stevens J, Wolff RK, Culver M, Carey JC, Copeland NG, Jenkins NA (1990) Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 62:187\u2013192","journal-title":"Cell"},{"key":"4771_CR8","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/ng0293-122","volume":"3","author":"E LEGIUS","year":"1993","unstructured":"LEGIUS E, MARCHUK D, COLLINS F, GLOVER T (1993) Somatic deletion of the neurofibromatosis type-1 gene in a neurofibrosarcoma supports a tumor suppressor gene hypothesis. Nat Genet 3:122\u2013126","journal-title":"Nat Genet"},{"key":"4771_CR9","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/S1470-2045(09)70033-6","volume":"10","author":"H Brems","year":"2009","unstructured":"Brems H, Beert E, de Ravel T, Legius E (2009) Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. Lancet Oncol 10:508\u2013515","journal-title":"Lancet Oncol"},{"key":"4771_CR10","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/1098-1004(200006)15:6<541::AID-HUMU6>3.0.CO;2-N","volume":"15","author":"LM Messiaen","year":"2000","unstructured":"Messiaen LM, Callens T, Mortier G, Beysen D, Vandenbroucke I, Van Roy N, Speleman F, Paepe AD (2000) Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat 15:541\u2013555","journal-title":"Hum Mutat"},{"key":"4771_CR11","doi-asserted-by":"publisher","first-page":"R80","DOI":"10.1186\/gb-2014-15-6-r80","volume":"15","author":"J Vogt","year":"2014","unstructured":"Vogt J, Bengesser K, Claes KB, Wimmer K, Mautner VF, van Minkelen R, Legius E, Brems H, Upadhyaya M, H\u00f6gel J, Lazaro C, Rosenbaum T, Bammert S, Messiaen L, Cooper DN, Kehrer-Sawatzki H (2014) SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints. Genome Biol 15:R80","journal-title":"Genome Biol"},{"key":"4771_CR12","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/gcc.20289","volume":"45","author":"K Wimmer","year":"2006","unstructured":"Wimmer K, Yao S, Claes K, Kehrer-Sawatzki H, Tinschert S, De Raedt T, Legius E, Callens T, Beiglb\u00f6ck H, Maertens O, Messiaen L (2006) Spectrum of single- and multiexon NF1 copy number changes in a cohort of 1,100 unselected NF1 patients. Genes Chromosomes Cancer 45:265\u2013276","journal-title":"Genes Chromosomes Cancer"},{"key":"4771_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1002371","volume":"7","author":"K Wimmer","year":"2011","unstructured":"Wimmer K, Callens T, Wernstedt A, Messiaen L (2011) The NF1 gene contains hotspots for L1 endonuclease-dependent de novo insertion. PLoS Genet 7:e1002371","journal-title":"PLoS Genet"},{"key":"4771_CR14","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00439-017-1766-y","volume":"136","author":"H Kehrer-Sawatzki","year":"2017","unstructured":"Kehrer-Sawatzki H, Mautner VF, Cooper DN (2017) Emerging genotype-phenotype relationships in patients with large NF1 deletions. Hum Genet 136:349\u2013376","journal-title":"Hum Genet"},{"key":"4771_CR15","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1086\/519562","volume":"81","author":"O Maertens","year":"2007","unstructured":"Maertens O, De Schepper S, Vandesompele J, Brerns H, Heyns I, Janssens S, Speleman F, Legius E, Messiaen L (2007) Molecular dissection of isolated disease features in mosaic neurofibromatosis type 1. Am J Hum Genet 81:243\u2013251","journal-title":"Am J Hum Genet"},{"key":"4771_CR16","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/sj.jid.5701095","volume":"128","author":"S De Schepper","year":"2008","unstructured":"De Schepper S, Maertens O, Callens T, Naeyaert JM, Lambert J, Messiaen L (2008) Somatic mutation analysis in NF1 caf\u00e9 au lait spots reveals two NF1 hits in the melanocytes. J Invest Dermatol 128:1050\u20131053","journal-title":"J Invest Dermatol"},{"key":"4771_CR17","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1002\/humu.23783","volume":"40","author":"C Brekelmans","year":"2019","unstructured":"Brekelmans C, Hollants S, De Groote C, Sohier N, Mar\u00e9chal M, Geris L, Luyten FP, Ginckels L, Sciot R, de Ravel T, De Smet L, Lammens J, Legius E, Brems H (2019) Neurofibromatosis type 1-related pseudarthrosis: beyond the pseudarthrosis site. Hum Mutat 40:1760\u20131767","journal-title":"Hum Mutat"},{"key":"4771_CR18","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1136\/jmedgenet-2014-102815","volume":"52","author":"DW Sant","year":"2015","unstructured":"Sant DW, Margraf RL, Stevenson DA, Grossmann AH, Viskochil DH, Hanson H, Everitt MD, Rios JJ, Elefteriou F, Hennessey T, Mao R (2015) Evaluation of somatic mutations in tibial pseudarthrosis samples in neurofibromatosis type 1. J Med Genet 52:256\u2013261","journal-title":"J Med Genet"},{"key":"4771_CR19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1086\/504441","volume":"79","author":"DA Stevenson","year":"2006","unstructured":"Stevenson DA, Zhou H, Ashrafi S, Messiaen LM, Carey JC, D\u2019Astous JL, Santora SD, Viskochil DH (2006) Double inactivation of NF1 in tibial pseudarthrosis. Am J Hum Genet 79:143\u2013148","journal-title":"Am J Hum Genet"},{"key":"4771_CR20","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/ng0296-144","volume":"12","author":"G Bollag","year":"1996","unstructured":"Bollag G, Clapp DW, Shih S, Adler F, Zhang YY, Thompson P, Lange BJ, Freedman MH, McCormick F, Jacks T, Shannon K (1996) Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet 12:144\u2013148","journal-title":"Nat Genet"},{"key":"4771_CR21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","volume":"170","author":"DK Simanshu","year":"2017","unstructured":"Simanshu DK, Nissley DV, McCormick F (2017) RAS proteins and their regulators in human disease. Cell 170:17\u201333","journal-title":"Cell"},{"key":"4771_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jbior.2014.04.002","volume":"55","author":"O Maertens","year":"2014","unstructured":"Maertens O, Cichowski K (2014) An expanding role for RAS GTPase activating proteins (RAS GAPs) in cancer. Adv Biol Regul 55:1\u201314","journal-title":"Adv Biol Regul"},{"key":"4771_CR23","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.ccr.2006.10.003","volume":"10","author":"S Courtois-Cox","year":"2006","unstructured":"Courtois-Cox S, Genther Williams SM, Reczek EE, Johnson BW, McGillicuddy LT, Johannessen CM, Hollstein PE, MacCollin M, Cichowski K (2006) A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 10:459\u2013472","journal-title":"Cancer Cell"},{"key":"4771_CR24","doi-asserted-by":"crossref","unstructured":"Akshintala S, Baldwin A, Liewehr DJ, Goodwin A, Blakeley JO, Gross AM, Steinberg SM, Dombi E, Widemann BC (2020) Longitudinal evaluation of peripheral nerve sheath tumors in neurofibromatosis type 1: growth analysis of plexiform neurofibromas and distinct nodular lesions. Neuro-Oncology","DOI":"10.1093\/neuonc\/noaa053"},{"key":"4771_CR25","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/gcc.20921","volume":"50","author":"E Beert","year":"2011","unstructured":"Beert E, Brems H, Daniels B, De Wever I, Van Calenbergh F, Schoenaers J, Debiec-Rychter M, Gevaert O, De Raedt T, Van den Bruel A, de Ravel T, Cichowski K, Kluwe L, Mautner V, Sciot R, Legius E (2011) Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. Genes Chromosomes & Cancer 50:1021\u20131032","journal-title":"Genes Chromosomes & Cancer"},{"key":"4771_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.humpath.2017.05.010","volume":"67","author":"MM Miettinen","year":"2017","unstructured":"Miettinen MM, Antonescu CR, Fletcher CDM, Kim A, Lazar AJ, Quezado MM, Reilly KM, Stemmer-Rachamimov A, Stewart DR, Viskochil D, Widemann B, Perry A (2017) Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview. Hum Pathol 67:1\u201310","journal-title":"Hum Pathol"},{"key":"4771_CR27","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1093\/neuonc\/noy013","volume":"20","author":"CS Higham","year":"2018","unstructured":"Higham CS, Dombi E, Rogiers A, Bhaumik S, Pans S, Connor SEJ, Miettinen M, Sciot R, Tirabosco R, Brems H, Baldwin A, Legius E, Widemann BC, Ferner RE (2018) The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors. Neuro-Oncology 20:818\u2013825","journal-title":"Neuro-Oncology"},{"key":"4771_CR28","doi-asserted-by":"crossref","unstructured":"Nelson CN, Dombi E, Rosenblum JS, Miettinen MM, Lehky TJ, Whitcomb PO, Hayes C, Scott G, Benzo S, Widemann BC, Chittiboina P (2019) Safe marginal resection of atypical neurofibromas in neurofibromatosis type 1. J Neurosurg:1\u201311","DOI":"10.1093\/neuros\/nyz310_143"},{"key":"4771_CR29","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/jso.23736","volume":"110","author":"NM Bernthal","year":"2014","unstructured":"Bernthal NM, Putnam A, Jones KB, Viskochil D, Randall RL (2014) The effect of surgical margins on outcomes for low grade MPNSTs and atypical neurofibroma. J Surg Oncol 110:813\u2013816","journal-title":"J Surg Oncol"},{"key":"4771_CR30","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1158\/1078-0432.CCR-17-0589","volume":"23","author":"DGR Evans","year":"2017","unstructured":"Evans DGR, Salvador H, Chang VY, Erez A, Voss SD, Schneider KW, Scott HS, Plon SE, Tabori U (2017) Cancer and central nervous system tumor surveillance in pediatric neurofibromatosis 1. Clin Cancer Res 23:e46\u2013e53","journal-title":"Clin Cancer Res"},{"key":"4771_CR31","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1093\/annonc\/mdm450","volume":"19","author":"RE Ferner","year":"2008","unstructured":"Ferner RE, Golding JF, Smith M, Calonje E, Jan W, Sanjayanathan V, O\u2019Doherty M (2008) [18F]2-Fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol 19:390\u2013394","journal-title":"Ann Oncol"},{"key":"4771_CR32","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00259-008-1038-0","volume":"36","author":"VS Warbey","year":"2009","unstructured":"Warbey VS, Ferner RE, Dunn JT, Calonje E, O\u2019Doherty MJ (2009) [18F]FDG PET\/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1. Eur J Nucl Med Mol Imaging 36:751\u2013757","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4771_CR33","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1093\/neuonc\/noz028","volume":"21","author":"A Pemov","year":"2019","unstructured":"Pemov A, Hansen NF, Sindiri S, Patidar R, Higham CS, Dombi E, Miettinen MM, Fetsch P, Brems H, Chandrasekharappa S, Jones K, Zhu B, Wei JS, Mullikin JC, Wallace MR, Khan J, Legius E, Widemann BC, Stewart DR, Program NCS, Laboratory NDCGR (2019) Low mutation burden and frequent loss of CDKN2A\/B and SMARCA2, but not PRC2, define pre-malignant neurofibromatosis type 1-associated atypical neurofibromas. Neuro-Oncology 21:981\u2013992","journal-title":"Neuro-Oncology"},{"key":"4771_CR34","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/gcc.2870100405","volume":"10","author":"E Legius","year":"1994","unstructured":"Legius E, Dierick H, Wu R, Hall B, Marynen P, Cassiman J, Glover T (1994) TP53 mutations are frequent in malignant NFI tumors. Genes Chromosomes Cancer 10:250\u2013255","journal-title":"Genes Chromosomes Cancer"},{"key":"4771_CR35","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nature13561","volume":"514","author":"T De Raedt","year":"2014","unstructured":"De Raedt T, Beert E, Pasmant E, Luscan A, Brems H, Ortonne N, Helin K, Hornick JL, Mautner V, Kehrer-Sawatzki H, Clapp W, Bradner J, Vidaud M, Upadhyaya M, Legius E, Cichowski K (2014) PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature 514:247\u2013251","journal-title":"Nature"},{"key":"4771_CR36","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/ng.3116","volume":"46","author":"M Zhang","year":"2014","unstructured":"Zhang M, Wang Y, Jones S, Sausen M, McMahon K, Sharma R, Wang Q, Belzberg AJ, Chaichana K, Gallia GL, Gokaslan ZL, Riggins GJ, Wolinksy JP, Wood LD, Montgomery EA, Hruban RH, Kinzler KW, Papadopoulos N, Vogelstein B, Bettegowda C (2014) Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. Nat Genet 46:1170\u20131172","journal-title":"Nat Genet"},{"key":"4771_CR37","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1038\/ng.3095","volume":"46","author":"W Lee","year":"2014","unstructured":"Lee W, Teckie S, Wiesner T, Ran L, Prieto Granada CN, Lin M, Zhu S, Cao Z, Liang Y, Sboner A, Tap WD, Fletcher JA, Huberman KH, Qin LX, Viale A, Singer S, Zheng D, Berger MF, Chen Y, Antonescu CR, Chi P (2014) PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet 46:1227\u20131232","journal-title":"Nat Genet"},{"key":"4771_CR38","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1086\/374821","volume":"72","author":"T De Raedt","year":"2003","unstructured":"De Raedt T, Brems H, Wolkenstein P, Vidaud D, Pilotti S, Perrone F, Mautner V, Frahm S, Sciot R, Legius E (2003) Elevated risk for MPNST in NF1 microdeletion patients. Am J Hum Genet 72:1288\u20131292","journal-title":"Am J Hum Genet"},{"key":"4771_CR39","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/humu.23929","volume":"41","author":"M Koczkowska","year":"2020","unstructured":"Koczkowska M, Callens T, Chen Y, Gomes A, Hicks AD, Sharp A, Johns E, Uhas KA, Armstrong L, Bosanko KA, Babovic-Vuksanovic D, Baker L, Basel DG, Bengala M, Bennett JT, Chambers C, Clarkson LK, Clementi M, Cort\u00e9s FM, Cunningham M, D\u2019Agostino MD, Delatycki MB, Digilio MC, Dosa L, Esposito S, Fox S, Freckmann ML, Fauth C, Giugliano T, Giustini S, Goetsch A, Goldberg Y, Greenwood RS, Griffis C, Gripp KW, Gupta P, Haan E, Hachen RK, Haygarth TL, Hern\u00e1ndez-Chico C, Hodge K, Hopkin RJ, Hudgins L, Janssens S, Keller K, Kelly-Mancuso G, Kochhar A, Korf BR, Lewis AM, Liebelt J, Lichty A, Listernick RH, Lyons MJ, Maystadt I, Martinez Ojeda M, Mc Dougall C, McGregor LK, Melis D, Mendelsohn N, Nowaczyk MJM, Ortenberg J, Panzer K, Pappas JG, Pierpont ME, Piluso G, Pinna V, Pivnick EK, Pond DA, Powell CM, Rogers C, Ruhrman Shahar N, Rutledge SL, Saletti V, Sandaradura SA, Santoro C, Schatz UA, Schreiber A, Scott DA, Sellars EA, Sheffer R, Siqveland E, Slopis JM, Smith R, Spalice A, Stockton DW, Streff H, Theos A, Tomlinson GE, Tran G, Trapane PL, Trevisson E, Ullrich NJ, Van den Ende J, Schrier Vergano SA, Wallace SE, Wangler MF, Weaver DD, Yohay KH, Zackai E, Zonana J, Zurcher V, KBM C, Eoli M, Martin Y, Wimmer K, De Luca A, Legius E, Messiaen LM (2020) Clinical spectrum of individuals with pathogenic NF1 missense variants affecting p.Met1149, p.Arg1276, and p.Lys1423: genotype-phenotype study in neurofibromatosis type 1. Hum Mutat 41:299\u2013315","journal-title":"Hum Mutat"},{"key":"4771_CR40","first-page":"A8","volume":"65","author":"C Lopez-Correa","year":"1999","unstructured":"Lopez-Correa C, Brems H, Lazaro C, Estivill X, Clementi M, Mason S, Marynen P, Legius E (1999)Inter-chromosomal homologous recombination could mediate large NF1 gene deletions. Am J Hum Genet 65:A8\u2013A8","journal-title":"Am J Hum Genet"},{"key":"4771_CR41","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/ng1920","volume":"38","author":"T De Raedt","year":"2006","unstructured":"De Raedt T, Stephens M, Heyns I, Brems H, Thijs D, Messiaen L, Stephens K, Lazaro C, Wimmer K, Kehrer-Sawatzki H, Vidaud D, Kluwe L, Marynen P, Legius E (2006) Conservation of hotspots for recombination in low-copy repeats associated with the NF1 microdeletion. Nat Genet 38:1419\u20131423","journal-title":"Nat Genet"},{"key":"4771_CR42","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/ajmg.a.30346","volume":"131A","author":"M Descheemaeker","year":"2004","unstructured":"Descheemaeker M, Roelandts K, De Raedt T, Brems H, Fryns J, Legius E (2004) Intelligence in individuals with a neurofibromatosis type 1 microdeletion. Am J Med Genet A 131A:325\u2013326","journal-title":"Am J Med Genet A"},{"key":"4771_CR43","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/sj.ejhg.5201419","volume":"13","author":"M Spiegel","year":"2005","unstructured":"Spiegel M, Oexle K, Horn D, Windt E, Buske A, Albrecht B, Prott EC, Seemanov\u00e1 E, Seidel J, Rosenbaum T, Jenne D, Kehrer-Sawatzki H, Tinschert S (2005) Childhood overgrowth in patients with common NF1 microdeletions. Eur J Hum Genet 13:883\u2013888","journal-title":"Eur J Hum Genet"},{"key":"4771_CR44","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ajhg.2017.12.001","volume":"102","author":"M Koczkowska","year":"2018","unstructured":"Koczkowska M, Chen Y, Callens T, Gomes A, Sharp A, Johnson S, Hsiao MC, Chen Z, Balasubramanian M, Barnett CP, Becker TA, Ben-Shachar S, Bertola DR, Blakeley JO, Burkitt-Wright EMM, Callaway A, Crenshaw M, Cunha KS, Cunningham M, D\u2019Agostino MD, Dahan K, De Luca A, Destr\u00e9e A, Dhamija R, Eoli M, Evans DGR, Galvin-Parton P, George-Abraham JK, Gripp KW, Guevara-Campos J, Hanchard NA, Hern\u00e1ndez-Chico C, Immken L, Janssens S, Jones KJ, Keena BA, Kochhar A, Liebelt J, Martir-Negron A, Mahoney MJ, Maystadt I, McDougall C, McEntagart M, Mendelsohn N, Miller DT, Mortier G, Morton J, Pappas J, Plotkin SR, Pond D, Rosenbaum K, Rubin K, Russell L, Rutledge LS, Saletti V, Schonberg R, Schreiber A, Seidel M, Siqveland E, Stockton DW, Trevisson E, Ullrich NJ, Upadhyaya M, van Minkelen R, Verhelst H, Wallace MR, Yap YS, Zackai E, Zonana J, Zurcher V, Claes K, Martin Y, Korf BR, Legius E, Messiaen LM (2018)Genotype-phenotype correlation in NF1: evidence for a more severe phenotype associated with missense mutations affecting NF1 codons 844-848. Am J Hum Genet 102:69\u201387","journal-title":"Am J Hum Genet"},{"key":"4771_CR45","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/s41436-018-0269-0","volume":"21","author":"M Koczkowska","year":"2019","unstructured":"Koczkowska M, Callens T, Gomes A, Sharp A, Chen Y, Hicks AD, Aylsworth AS, Azizi AA, Basel DG, Bellus G, Bird LM, Blazo MA, Burke LW, Cannon A, Collins F, De Filippo C, Denayer E, Digilio MC, Dills SK, Dosa L, Greenwood RS, Griffis C, Gupta P, Hachen RK, Hern\u00e1ndez-Chico C, Janssens S, Jones KJ, Jordan JT, Kannu P, Korf BR, Lewis AM, Listernick RH, Lonardo F, Mahoney MJ, Ojeda MM, McDonald MT, McDougall C, Mendelsohn N, Miller DT, Mori M, Oostenbrink R, Perreault S, Pierpont ME, Piscopo C, Pond DA, Randolph LM, Rauen KA, Rednam S, Rutledge SL, Saletti V, Schaefer GB, Schorry EK, Scott DA, Shugar A, Siqveland E, Starr LJ, Syed A, Trapane PL, Ullrich NJ, Wakefield EG, Walsh LE, Wangler MF, Zackai E, KBM C, Wimmer K, van Minkelen R, De Luca A, Martin Y, Legius E, Messiaen LM (2019) Expanding the clinical phenotype of individuals with a 3-bp in-frame deletion of the NF1 gene (c.2970_2972del): an update of genotype-phenotype correlation. Genet Med 21:867\u2013876","journal-title":"Genet Med"},{"key":"4771_CR46","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/humu.22832","volume":"36","author":"K Rojnueangnit","year":"2015","unstructured":"Rojnueangnit K, Xie J, Gomes A, Sharp A, Callens T, Chen Y, Liu Y, Cochran M, Abbott MA, Atkin J, Babovic-Vuksanovic D, Barnett CP, Crenshaw M, Bartholomew DW, Basel L, Bellus G, Ben-Shachar S, Bialer MG, Bick D, Blumberg B, Cortes F, David KL, Destree A, Duat-Rodriguez A, Earl D, Escobar L, Eswara M, Ezquieta B, Frayling IM, Frydman M, Gardner K, Gripp KW, Hern\u00e1ndez-Chico C, Heyrman K, Ibrahim J, Janssens S, Keena BA, Llano-Rivas I, Leppig K, McDonald M, Misra VK, Mulbury J, Narayanan V, Orenstein N, Galvin-Parton P, Pedro H, Pivnick EK, Powell CM, Randolph L, Raskin S, Rosell J, Rubin K, Seashore M, Schaaf CP, Scheuerle A, Schultz M, Schorry E, Schnur R, Siqveland E, Tkachuk A, Tonsgard J, Upadhyaya M, Verma IC, Wallace S, Williams C, Zackai E, Zonana J, Lazaro C, Claes K, Korf B, Martin Y, Legius E, Messiaen L (2015) High incidence of Noonan syndrome features including short stature and pulmonic stenosis in patients carrying NF1 missense mutations affecting p.Arg1809: genotype-phenotype correlation. Hum Mutat 36:1052\u20131063","journal-title":"Hum Mutat"},{"key":"4771_CR47","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1086\/510781","volume":"80","author":"M Upadhyaya","year":"2007","unstructured":"Upadhyaya M, Huson SM, Davies M, Thomas N, Chuzhanova N, Giovannini S, Evans DG, Howard E, Kerr B, Griffiths S, Consoli C, Side L, Adams D, Pierpont M, Hachen R, Barnicoat A, Li H, Wallace P, Van Biervliet JP, Stevenson D, Viskochil D, Baralle D, Haan E, Riccardi V, Turnpenny P, Lazaro C, Messiaen L (2007) An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. Am J Hum Genet 80:140\u2013151","journal-title":"Am J Hum Genet"},{"key":"4771_CR48","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1038\/ejhg.2014.243","volume":"23","author":"V Pinna","year":"2015","unstructured":"Pinna V, Lanari V, Daniele P, Consoli F, Agolini E, Margiotti K, Bottillo I, Torrente I, Bruselles A, Fusilli C, Ficcadenti A, Bargiacchi S, Trevisson E, Forzan M, Giustini S, Leoni C, Zampino G, Digilio MC, Dallapiccola B, Clementi M, Tartaglia M, De Luca A (2015) p.Arg1809Cys substitution in neurofibromin is associated with a distinctive NF1 phenotype without neurofibromas. Eur J Hum Genet 23:1068\u20131071","journal-title":"Eur J Hum Genet"},{"key":"4771_CR49","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41436-019-0598-7","volume":"22","author":"DG Evans","year":"2020","unstructured":"Evans DG, Hartley CL, Smith PT, King AT, Bowers NL, Tobi S, Wallace AJ, Perry M, Anup R, Lloyd SKW, Rutherford SA, Hammerbeck-Ward C, Pathmanaban ON, Stapleton E, Freeman SR, Kellett M, Halliday D, Parry A, Gair JJ, Axon P, Laitt R, Thomas O, Afridi SK, Obholzer R, Duff C, Stivaros SM, Vassallo G, Harkness EF, Smith MJ, group ESNr (2020) Incidence of mosaicism in 1055 de novo NF2 cases: much higher than previous estimates with high utility of next-generation sequencing. Genet Med 22:53\u201359","journal-title":"Genet Med"},{"key":"4771_CR50","doi-asserted-by":"crossref","unstructured":"Payne JM, Haebich KM, MacKenzie R, Walsh KS, Hearps SJC, Coghill D, Barton B, Pride NA, Ullrich NJ, Tonsgard JH, Viskochil D, Schorry EK, Klesse L, Fisher MJ, Gutmann DH, Rosser T, Packer RJ, Korf B, Acosta MT, Bellgrove MA, North KN (2019) Cognition, ADHD symptoms, and functional impairment in children and adolescents with neurofibromatosis type 1. J Atten Disord:1087054719894384","DOI":"10.1177\/1087054719894384"},{"key":"4771_CR51","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1001\/jamapsychiatry.2016.2600","volume":"73","author":"SM Morris","year":"2016","unstructured":"Morris SM, Acosta MT, Garg S, Green J, Huson S, Legius E, North KN, Payne JM, Plasschaert E, Frazier TW, Weiss LA, Zhang Y, Gutmann DH, Constantino JN (2016) Disease burden and symptom structure of autism in neurofibromatosis type 1: a study of the International NF1-ASD Consortium Team (INFACT). JAMA Psychiatry 73:1276\u20131284","journal-title":"JAMA Psychiatry"},{"key":"4771_CR52","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/s41436-020-0752-2","volume":"22","author":"MJ Ottenhoff","year":"2020","unstructured":"Ottenhoff MJ, Rietman AB, Mous SE, Plasschaert E, Gawehns D, Brems H, Oostenbrink R, van Minkelen R, Nellist M, Schorry E, Legius E, Moll HA, Elgersma Y, Team E-N(2020) Examination of the genetic factors underlying the cognitive variability associated with neurofibromatosis type 1. Genet Med 22:889\u2013897","journal-title":"Genet Med"},{"key":"4771_CR53","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.eplepsyres.2013.02.021","volume":"105","author":"C Barba","year":"2013","unstructured":"Barba C, Jacques T, Kahane P, Polster T, Isnard J, Leijten FS, Ozkara C, Tassi L, Giordano F, Castagna M, John A, Oz B, Salon C, Streichenberger N, Cross JH, Guerrini R (2013) Epilepsy surgery in neurofibromatosis type 1. Epilepsy Res 105:384\u2013395","journal-title":"Epilepsy Res"},{"key":"4771_CR54","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00401-019-02002-2","volume":"139","author":"JS Nix","year":"2020","unstructured":"Nix JS, Blakeley J, Rodriguez FJ (2020) An update on the central nervous system manifestations of neurofibromatosis type 1. Acta Neuropathol 139:625\u2013641","journal-title":"Acta Neuropathol"},{"key":"4771_CR55","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","volume":"20","author":"J Fangusaro","year":"2019","unstructured":"Fangusaro J, Onar-Thomas A, Young Poussaint T, Wu S, Ligon AH, Lindeman N, Banerjee A, Packer RJ, Kilburn LB, Goldman S, Pollack IF, Qaddoumi I, Jakacki RI, Fisher PG, Dhall G, Baxter P, Kreissman SG, Stewart CF, Jones DTW, Pfister SM, Vezina G, Stern JS, Panigrahy A, Patay Z, Tamrazi B, Jones JY, Haque SS, Enterline DS, Cha S, Fisher MJ, Doyle LA, Smith M, Dunkel IJ, Fouladi M (2019) Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol 20:1011\u20131022","journal-title":"Lancet Oncol"},{"key":"4771_CR56","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/S0022-3476(95)70159-1","volume":"127","author":"R Listernick","year":"1995","unstructured":"Listernick R, Darling C, Greenwald M, Strauss L, Charrow J (1995) Optic pathway tumors in children: the effect of neurofibromatosis type 1 on clinical manifestations and natural history. J Pediatr 127:718\u2013722","journal-title":"J Pediatr"},{"key":"4771_CR57","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1212\/01.WNL.0000144341.16830.01","volume":"63","author":"R Listernick","year":"2004","unstructured":"Listernick R, Ferner RE, Piersall L, Sharif S, Gutmann DH, Charrow J (2004)Late-onset optic pathway tumors in children with neurofibromatosis 1. Neurology 63:1944\u20131946","journal-title":"Neurology"},{"key":"4771_CR58","doi-asserted-by":"crossref","unstructured":"Santoro C, Perrotta S, Picariello S, Scilipoti M, Cirillo M, Quaglietta L, Cinalli G, Cioffi D, Di Iorgi N, Maghnie M, Gallizia A, Parpagnoli M, Messa F, De Sanctis L, Vannelli S, Marzuillo P, Miraglia Del Giudice E, Grandone A (2020) Pretreatment endocrine disorders due to optic pathway gliomas in pediatric neurofibromatosis type 1: multicenter study. J Clin Endocrinol Metab 105","DOI":"10.1210\/clinem\/dgaa138"},{"key":"4771_CR59","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ejpn.2015.03.002","volume":"19","author":"S Caen","year":"2015","unstructured":"Caen S, Cassiman C, Legius E, Casteels I (2015) Comparative study of the ophthalmological examinations in neurofibromatosis type 1. Proposal for a new screening algorithm. Eur J Paediatr Neurol 19:415\u2013422","journal-title":"Eur J Paediatr Neurol"},{"key":"4771_CR60","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41591-018-0263-8","volume":"25","author":"F D\u2019Angelo","year":"2019","unstructured":"D\u2019Angelo F, Ceccarelli M, Tala GL, Zhang J, Frattini V, Caruso FP, Lewis G, Alfaro KD, Bauchet L, Berzero G, Cachia D, Cangiano M, Capelle L, de Groot J, DiMeco F, Ducray F, Farah W, Finocchiaro G, Goutagny S, Kamiya-Matsuoka C, Lavarino C, Loiseau H, Lorgis V, Marras CE, McCutcheon I, Nam DH, Ronchi S, Saletti V, Seizeur R, Slopis J, Su\u00f1ol M, Vandenbos F, Varlet P, Vidaud D, Watts C, Tabar V, Reuss DE, Kim SK, Meyronet D, Mokhtari K, Salvador H, Bhat KP, Eoli M, Sanson M, Lasorella A, Iavarone A (2019) The molecular landscape of glioma in patients with neurofibromatosis 1. Nat Med 25:176\u2013187","journal-title":"Nat Med"},{"key":"4771_CR61","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1161\/STROKEAHA.115.011406","volume":"47","author":"AR Terry","year":"2016","unstructured":"Terry AR, Jordan JT, Schwamm L, Plotkin SR (2016) Increased risk of cerebrovascular disease among patients with neurofibromatosis type 1: population-based approach. Stroke 47:60\u201365","journal-title":"Stroke"},{"key":"4771_CR62","doi-asserted-by":"publisher","first-page":"e476","DOI":"10.1542\/peds.2009-0152","volume":"124","author":"D Rea","year":"2009","unstructured":"Rea D, Brandsema JF, Armstrong D, Parkin PC, deVeber G, MacGregor D, Logan WJ, Askalan R (2009) Cerebral arteriopathy in children with neurofibromatosis type 1. Pediatrics 124:e476\u2013e483","journal-title":"Pediatrics"},{"key":"4771_CR63","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1136\/jnnp.2007.136457","volume":"79","author":"AG Cairns","year":"2008","unstructured":"Cairns AG, North KN (2008) Cerebrovascular dysplasia in neurofibromatosis type 1. J Neurol Neurosurg Psychiatry 79:1165\u20131170","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"4771_CR64","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/brain\/awg016","volume":"126","author":"JS Guillamo","year":"2003","unstructured":"Guillamo JS, Cr\u00e9ange A, Kalifa C, Grill J, Rodriguez D, Doz F, Barbarot S, Zerah M, Sanson M, Bastuji-Garin S, Wolkenstein P, France RN (2003) Prognostic factors of CNS tumours in neurofibromatosis 1 (NF1): a retrospective study of 104 patients. Brain 126:152\u2013160","journal-title":"Brain"},{"key":"4771_CR65","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1086\/320121","volume":"68","author":"SA Rasmussen","year":"2001","unstructured":"Rasmussen SA, Yang Q, Friedman JM (2001) Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am J Hum Genet 68:1110\u20131118","journal-title":"Am J Hum Genet"},{"key":"4771_CR66","doi-asserted-by":"publisher","DOI":"10.1542\/peds.104.4.e49","volume":"104","author":"PD Griffiths","year":"1999","unstructured":"Griffiths PD, Blaser S, Mukonoweshuro W, Armstrong D, Milo-Mason G, Cheung S (1999) Neurofibromatosis bright objects in children with neurofibromatosis type 1: a proliferative potential? Pediatrics 104:e49","journal-title":"Pediatrics"},{"key":"4771_CR67","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.nicl.2014.04.005","volume":"4","author":"T Billiet","year":"2014","unstructured":"Billiet T, M\u00e4dler B, D\u2019Arco F, Peeters R, Deprez S, Plasschaert E, Leemans A, Zhang H, den Bergh BV, Vandenbulcke M, Legius E, Sunaert S, Emsell L (2014) Characterizing the microstructural basis of \u201cunidentified bright objects\u201d in neurofibromatosis type 1: a combined in vivo multicomponent T2 relaxation and multi-shell diffusion MRI analysis. Neuroimage Clin 4:649\u2013658","journal-title":"Neuroimage Clin"},{"key":"4771_CR68","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1212\/WNL.54.4.914","volume":"54","author":"BD Moore","year":"2000","unstructured":"Moore BD, Slopis JM, Jackson EF, De Winter AE, Leeds NE (2000) Brain volume in children with neurofibromatosis type 1: relation to neuropsychological status. Neurology 54:914\u2013920","journal-title":"Neurology"},{"key":"4771_CR69","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11060-013-1293-1","volume":"116","author":"R Nguyen","year":"2014","unstructured":"Nguyen R, Jett K, Harris GJ, Cai W, Friedman JM, Mautner VF (2014) Benign whole body tumor volume is a risk factor for malignant peripheral nerve sheath tumors in neurofibromatosis type 1. J Neuro-Oncol 116:307\u2013313","journal-title":"J Neuro-Oncol"},{"key":"4771_CR70","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.radonc.2019.03.015","volume":"137","author":"R Miao","year":"2019","unstructured":"Miao R, Wang H, Jacobson A, Lietz AP, Choy E, Raskin KA, Schwab JH, Deshpande V, Nielsen GP, DeLaney TF, Cote GM, Hornicek FJ, Chen YE (2019)Radiation-induced and neurofibromatosis-associated malignant peripheral nerve sheath tumors (MPNST) have worse outcomes than sporadic MPNST. Radiother Oncol 137:61\u201370","journal-title":"Radiother Oncol"},{"key":"4771_CR71","doi-asserted-by":"publisher","first-page":"961-970.e968","DOI":"10.1016\/j.wneu.2017.06.010","volume":"105","author":"R Yamanaka","year":"2017","unstructured":"Yamanaka R, Hayano A (2017)Radiation-induced malignant peripheral nerve sheath tumors: a systematic review. World Neurosurg 105:961-970.e968","journal-title":"World Neurosurg"},{"key":"4771_CR72","doi-asserted-by":"publisher","first-page":"e359","DOI":"10.1097\/MPH.0000000000001156","volume":"40","author":"F Malbari","year":"2018","unstructured":"Malbari F, Spira M, Knight PB, Zhu C, Roth M, Gill J, Abbott R, Levy AS (2018) Malignant peripheral nerve sheath tumors in neurofibromatosis: impact of family history. J Pediatr Hematol Oncol 40:e359\u2013e363","journal-title":"J Pediatr Hematol Oncol"},{"key":"4771_CR73","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1038\/ng2113","volume":"39","author":"H Brems","year":"2007","unstructured":"Brems H, Chmara M, Sahbatou M, Denayer E, Taniguchi K, Kato R, Somers R, Messiaen L, De Schepper S, Fryns J-P, Cools J, Marynen P, Thomas G, Yoshimura A, Legius E (2007) Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet 39:1120\u20131126","journal-title":"Nat Genet"},{"key":"4771_CR74","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1001\/jama.2009.1663","volume":"302","author":"L Messiaen","year":"2009","unstructured":"Messiaen L, Yao S, Brems H, Callens T, Sathienkijkanchai A, Denayer E, Spencer E, Arn P, Babovic-Vuksanovic D, Bay C, Bobele G, Cohen BH, Escobar L, Eunpu D, Grebe T, Greenstein R, Hachen R, Irons M, Kronn D, Lemire E, Leppig K, Lim C, McDonald M, Narayanan V, Pearn A, Pedersen R, Powell B, Shapiro LR, Skidmore D, Tegay D, Thiese H, Zackai EH, Vijzelaar R, Taniguchi K, Ayada T, Okamoto F, Yoshimura A, Parret A, Korf B, Legius E (2009) Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome. Jama-Journal of the American Medical Association 302:2111\u20132118","journal-title":"Jama-Journal of the American Medical Association"},{"key":"4771_CR75","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/ejhg.2014.145","volume":"23","author":"E Pasmant","year":"2015","unstructured":"Pasmant E, Parfait B, Luscan A, Goussard P, Briand-Suleau A, Laurendeau I, Fouveaut C, Leroy C, Montadert A, Wolkenstein P, Vidaud M, Vidaud D (2015) Neurofibromatosis type 1 molecular diagnosis: what can NGS do for you when you have a large gene with loss of function mutations? Eur J Hum Genet 23:596\u2013601","journal-title":"Eur J Hum Genet"},{"key":"4771_CR76","doi-asserted-by":"publisher","first-page":"7497","DOI":"10.1073\/pnas.1607298113","volume":"113","author":"T Dunzendorfer-Matt","year":"2016","unstructured":"Dunzendorfer-Matt T, Mercado EL, Maly K, McCormick F, Scheffzek K (2016) The neurofibromin recruitment factor Spred1 binds to the GAP related domain without affecting Ras inactivation. Proc Natl Acad Sci U S A 113:7497\u20137502","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4771_CR77","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1074\/jbc.M115.703710","volume":"291","author":"Y Hirata","year":"2016","unstructured":"Hirata Y, Brems H, Suzuki M, Kanamori M, Okada M, Morita R, Llano-Rivas I, Ose T, Messiaen L, Legius E, Yoshimura A (2016) Interaction between a domain of the negative regulator of the Ras-ERK pathway, SPRED1 protein, and the GTPase-activating protein-related domain of neurofibromin is implicated in Legius syndrome and neurofibromatosis type 1. J Biol Chem 291:3124\u20133134","journal-title":"J Biol Chem"},{"key":"4771_CR78","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1101\/gad.190876.112","volume":"26","author":"IB Stowe","year":"2012","unstructured":"Stowe IB, Mercado EL, Stowe TR, Bell EL, Oses-Prieto JA, Hern\u00e1ndez H, Burlingame AL, McCormick F (2012) A shared molecular mechanism underlies the human rasopathies Legius syndrome and neurofibromatosis 1. Genes Dev 26:1421\u20131426","journal-title":"Genes Dev"},{"key":"4771_CR79","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2302\/kjm.58.73","volume":"58","author":"A Yoshimura","year":"2009","unstructured":"Yoshimura A (2009) Regulation of cytokine signaling by the SOCS and Spred family proteins. Keio J Med 58:73\u201383","journal-title":"Keio J Med"},{"key":"4771_CR80","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/jmg.39.8.571","volume":"39","author":"E Legius","year":"2002","unstructured":"Legius E, Schrander-Stumpel C, Schollen E, Pulles-Heintzberger C, Gewillig M, Fryns J (2002) PTPN11 mutations in LEOPARD syndrome. J Med Genet 39:571\u2013574","journal-title":"J Med Genet"},{"key":"4771_CR81","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1086\/341528","volume":"71","author":"MC Digilio","year":"2002","unstructured":"Digilio MC, Conti E, Sarkozy A, Mingarelli R, Dottorini T, Marino B, Pizzuti A, Dallapiccola B (2002) Grouping of multiple-lentigines\/LEOPARD and Noonan syndromes on the PTPN11 gene. Am J Hum Genet 71:389\u2013394","journal-title":"Am J Hum Genet"},{"key":"4771_CR82","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1038\/ng2073","volume":"39","author":"B Pandit","year":"2007","unstructured":"Pandit B, Sarkozy A, Pennacchio LA, Carta C, Oishi K, Martinelli S, Pogna EA, Schackwitz W, Ustaszewska A, Landstrom A, Bos JM, Ommen SR, Esposito G, Lepri F, Faul C, Mundel P, L\u00f3pez Siguero JP, Tenconi R, Selicorni A, Rossi C, Mazzanti L, Torrente I, Marino B, Digilio MC, Zampino G, Ackerman MJ, Dallapiccola B, Tartaglia M, Gelb BD (2007)Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet 39:1007\u20131012","journal-title":"Nat Genet"},{"key":"4771_CR83","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/jmedgenet-2015-103177","volume":"53","author":"E Conboy","year":"2016","unstructured":"Conboy E, Dhamija R, Wang M, Xie J, Dyck PJ, Bridges AG, Spinner RJ, Clayton AC, Watson RE, Messiaen L, Babovic-Vuksanovic D (2016) Paraspinal neurofibromas and hypertrophic neuropathy in Noonan syndrome with multiple lentigines. J Med Genet 53:123\u2013126","journal-title":"J Med Genet"},{"key":"4771_CR84","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/jhg.2015.114","volume":"61","author":"Y Aoki","year":"2016","unstructured":"Aoki Y, Niihori T, Inoue S, Matsubara Y (2016) Recent advances in RASopathies. J Hum Genet 61:33\u201339","journal-title":"J Hum Genet"},{"key":"4771_CR85","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/hmg\/ddn336","volume":"18","author":"K Oishi","year":"2009","unstructured":"Oishi K, Zhang H, Gault WJ, Wang CJ, Tan CC, Kim IK, Ying H, Rahman T, Pica N, Tartaglia M, Mlodzik M, Gelb BD (2009)Phosphatase-defective LEOPARD syndrome mutations in PTPN11 gene have gain-of-function effects during Drosophila development. Hum Mol Genet 18:193\u2013201","journal-title":"Hum Mol Genet"},{"key":"4771_CR86","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1136\/jmedgenet-2018-105664","volume":"56","author":"M Suerink","year":"2019","unstructured":"Suerink M, Ripperger T, Messiaen L, Menko FH, Bourdeaut F, Colas C, Jongmans M, Goldberg Y, Nielsen M, Muleris M, van Kouwen M, Slavc I, Kratz C, Vasen HF, Brugi\u0450res L, Legius E, Wimmer K (2019) Constitutional mismatch repair deficiency as a differential diagnosis of neurofibromatosis type 1: consensus guidelines for testing a child without malignancy. J Med Genet 56:53\u201362","journal-title":"J Med Genet"},{"key":"4771_CR87","doi-asserted-by":"crossref","unstructured":"Wimmer K, Kratz CP, Vasen HF, Caron O, Colas C, Entz-Werle N, Gerdes AM, Goldberg Y, Ilencikova D, Muleris M, Duval A, Lavoine N, Ruiz-Ponte C, Slavc I, Burkhardt B, Brugieres L, (C4CMMRD)E-CCfC(2014) Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium \u2018care for CMMRD\u2019 (C4CMMRD). J Med Genet 51:355\u2013365","DOI":"10.1136\/jmedgenet-2014-102284"},{"key":"4771_CR88","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/cge.12904","volume":"91","author":"K Wimmer","year":"2017","unstructured":"Wimmer K, Rosenbaum T, Messiaen L (2017) Connections between constitutional mismatch repair deficiency syndrome and neurofibromatosis type 1. Clin Genet 91:507\u2013519","journal-title":"Clin Genet"},{"key":"4771_CR89","doi-asserted-by":"publisher","first-page":"13","DOI":"10.5070\/D396R0V4FR","volume":"17","author":"R Spritz","year":"2011","unstructured":"Spritz R (2011) Letter: Misdiagnosis of \u201cneurofibromatosis\u201d in patients with piebaldism. Dermatol Online J 17:13","journal-title":"Dermatol Online J"},{"key":"4771_CR90","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/ajmg.a.35297","volume":"158A","author":"CA Stevens","year":"2012","unstructured":"Stevens CA, Chiang PW, Messiaen LM (2012) Caf\u00e9-au-lait macules and intertriginous freckling in piebaldism: clinical overlap with neurofibromatosis type 1 and Legius syndrome. Am J Med Genet A 158A:1195\u20131199","journal-title":"Am J Med Genet A"},{"key":"4771_CR91","doi-asserted-by":"publisher","first-page":"281-285.e284","DOI":"10.1016\/j.jpeds.2018.09.070","volume":"205","author":"P Romanet","year":"2019","unstructured":"Romanet P, Philibert P, Fina F, Cuny T, Roche C, Ouafik L, Paris F, Reynaud R, Barlier A (2019) Using digital droplet polymerase chain reaction to detect the mosaic GNAS mutations in whole blood DNA or circulating cell-free DNA in fibrous dysplasia and McCune-Albright syndrome. J Pediatr 205:281-285.e284","journal-title":"J Pediatr"},{"key":"4771_CR92","doi-asserted-by":"crossref","unstructured":"Spencer T, Pan KS, Collins MT, Boyce AM (2019) The clinical spectrum of McCune-Albright syndrome and its management. Horm Res Paediatr:1\u201310","DOI":"10.1159\/000504802"},{"key":"4771_CR93","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1097\/CCO.0000000000000579","volume":"31","author":"D Halliday","year":"2019","unstructured":"Halliday D, Parry A, Evans DG (2019) Neurofibromatosis type 2 and related disorders. Curr Opin Oncol 31:562\u2013567","journal-title":"Curr Opin Oncol"},{"key":"4771_CR94","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1086\/513207","volume":"80","author":"TJ Hulsebos","year":"2007","unstructured":"Hulsebos TJ, Plomp AS, Wolterman RA, Robanus-Maandag EC, Baas F, Wesseling P (2007) Germline mutation of INI1\/SMARCB1 in familial schwannomatosis. Am J Hum Genet 80:805\u2013810","journal-title":"Am J Hum Genet"},{"key":"4771_CR95","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/ng.2855","volume":"46","author":"A Piotrowski","year":"2014","unstructured":"Piotrowski A, Xie J, Liu YF, Poplawski AB, Gomes AR, Madanecki P, Fu C, Crowley MR, Crossman DK, Armstrong L, Babovic-Vuksanovic D, Bergner A, Blakeley JO, Blumenthal AL, Daniels MS, Feit H, Gardner K, Hurst S, Kobelka C, Lee C, Nagy R, Rauen KA, Slopis JM, Suwannarat P, Westman JA, Zanko A, Korf BR, Messiaen LM (2014) Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas. Nat Genet 46:182\u2013187","journal-title":"Nat Genet"},{"key":"4771_CR96","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1126\/science.aap7607","volume":"362","author":"M Steklov","year":"2018","unstructured":"Steklov M, Pandolfi S, Baietti MF, Batiuk A, Carai P, Najm P, Zhang M, Jang H, Renzi F, Cai Y, Abbasi Asbagh L, Pastor T, De Troyer M, Simicek M, Radaelli E, Brems H, Legius E, Tavernier J, Gevaert K, Impens F, Messiaen L, Nussinov R, Heymans S, Eyckerman S, Sablina AA (2018) Mutations in LZTR1 drive human disease by dysregulating RAS ubiquitination. Science 362:1177\u20131182","journal-title":"Science"},{"key":"4771_CR97","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1093\/neuonc\/noy009","volume":"20","author":"C Louvrier","year":"2018","unstructured":"Louvrier C, Pasmant E, Briand-Suleau A, Cohen J, Nitschk\u00e9 P, Nectoux J, Orhant L, Zordan C, Goizet C, Goutagny S, Lallemand D, Vidaud M, Vidaud D, Kalamarides M, Parfait B (2018) Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis. Neuro-Oncology 20:917\u2013929","journal-title":"Neuro-Oncology"},{"key":"4771_CR98","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","volume":"375","author":"E Dombi","year":"2016","unstructured":"Dombi E, Baldwin A, Marcus LJ, Fisher MJ, Weiss B, Kim A, Whitcomb P, Martin S, Aschbacher-Smith LE, Rizvi TA, Wu J, Ershler R, Wolters P, Therrien J, Glod J, Belasco JB, Schorry E, Brofferio A, Starosta AJ, Gillespie A, Doyle AL, Ratner N, Widemann BC (2016) Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N Engl J Med 375:2550\u20132560","journal-title":"N Engl J Med"},{"key":"4771_CR99","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","volume":"382","author":"AM Gross","year":"2020","unstructured":"Gross AM, Wolters PL, Dombi E, Baldwin A, Whitcomb P, Fisher MJ, Weiss B, Kim A, Bornhorst M, Shah AC, Martin S, Roderick MC, Pichard DC, Carbonell A, Paul SM, Therrien J, Kapustina O, Heisey K, Clapp DW, Zhang C, Peer CJ, Figg WD, Smith M, Glod J, Blakeley JO, Steinberg SM, Venzon DJ, Doyle LA, Widemann BC (2020) Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med 382:1430\u20131442","journal-title":"N Engl J Med"},{"key":"4771_CR100","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1093\/neuonc\/now282","volume":"19","author":"A Banerjee","year":"2017","unstructured":"Banerjee A, Jakacki RI, Onar-Thomas A, Wu S, Nicolaides T, Young Poussaint T, Fangusaro J, Phillips J, Perry A, Turner D, Prados M, Packer RJ, Qaddoumi I, Gururangan S, Pollack IF, Goldman S, Doyle LA, Stewart CF, Boyett JM, Kun LE, Fouladi M (2017) A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. Neuro-Oncology 19:1135\u20131144","journal-title":"Neuro-Oncology"},{"key":"4771_CR101","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1186\/s12885-019-6442-2","volume":"19","author":"S Perreault","year":"2019","unstructured":"Perreault S, Larouche V, Tabori U, Hawkin C, Lipp\u00e9 S, Ellezam B, D\u00e9carie JC, Th\u00e9oret Y, M\u00e9tras M, Sultan S, Cantin \u00c9, Routhier M, Caru M, Legault G, Bouffet \u00c9, Lafay-Cousin L, Hukin J, Erker C, Jabado N (2019) A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK\/ERK pathway: TRAM-01. BMC Cancer 19:1250","journal-title":"BMC Cancer"},{"key":"4771_CR102","doi-asserted-by":"crossref","unstructured":"Klesse LJ, Jordan JT, Radtke HB, Rosser T, Schorry E, Ullrich N, Viskochil D, Knight P, Plotkin SR, Yohay K (2020) The use of MEK inhibitors in neurofibromatosis type 1-associated tumors and management of toxicities. Oncologist","DOI":"10.1634\/theoncologist.2020-0069"},{"key":"4771_CR103","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1093\/neuonc\/noaa036","volume":"22","author":"RJ Packer","year":"2020","unstructured":"Packer RJ, Iavarone A, Jones DTW, Blakeley JO, Bouffet E, Fisher MJ, Hwang E, Hawkins C, Kilburn L, MacDonald T, Pfister SM, Rood B, Rodriguez FJ, Tabori U, Ramaswamy V, Zhu Y, Fangusaro J, Johnston SA, Gutmann DH (2020) Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference. Neuro-Oncology 22:773\u2013784","journal-title":"Neuro-Oncology"}],"container-title":["Child's Nervous System"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00381-020-04771-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00381-020-04771-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00381-020-04771-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,17]],"date-time":"2022-04-17T19:05:10Z","timestamp":1650222310000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00381-020-04771-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,29]]},"references-count":103,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["4771"],"URL":"https:\/\/doi.org\/10.1007\/s00381-020-04771-8","relation":{},"ISSN":["0256-7040","1433-0350"],"issn-type":[{"value":"0256-7040","type":"print"},{"value":"1433-0350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,29]]},"assertion":[{"value":"25 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Eric Legius received consulting fees from AstraZeneca and SpringWorks Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}